HIVAC-1e

elicits a weak antibody & T-cell response in some people; no longer undergoing trials as an Aids Vaccine; studies are underway to examine HIVAC-1e in vaccinia-naive persons; recombinant vaccine using a vaccinia vector & gp160; coordinate with HIV envelope protein gp160(NM)

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Vaccinia 02/01/1999 - "In an initial phase I trial, 11 vaccinia-naïve volunteers were vaccinated with HIVAC-1e, followed by a booster with baculovirus-derived gp160 (VaxSyn). " 08/01/1992 - "Vaccination with HIVAC-1e was safe in vaccinia-naive, healthy adults and could induce both humoral and cell-mediated gp160-specific immune responses." 02/01/1999 - "Using the same strategy in 29 vaccinia-naïve volunteers, priming with HIVAC-1e was demonstrated as a key determinant of the epitope specificity and magnitude of antibody responses to gp160 [195278]." 03/09/1991 - "In-vitro T-cell proliferative responses to one or more HIV antigen preparations developed in 13 of 16 vaccinia-primed subjects inoculated with HIVAC-1e. " 03/09/1991 - "In a randomised phase I trial of a recombinant vaccina virus vaccine expressing the gp160 envelope gene of the human immunodeficiency virus (HIVAC-1e) 35 healthy, HIV-seronegative males, 31 of whom had a history of smallpox immunisation and 4 of whom were vaccinia naive, were vaccinated and then boosted 8 weeks later with HIVAC-1e or standard NY strain vaccinia virus. "
2.	Smallpox (Variola) 03/09/1991 - "In a randomised phase I trial of a recombinant vaccina virus vaccine expressing the gp160 envelope gene of the human immunodeficiency virus (HIVAC-1e) 35 healthy, HIV-seronegative males, 31 of whom had a history of smallpox immunisation and 4 of whom were vaccinia naive, were vaccinated and then boosted 8 weeks later with HIVAC-1e or standard NY strain vaccinia virus. "

Related Drugs and Biologics

1.	Vaccines
2.	Proteins (Proteins, Gene)
3.	Antigens
4.	Epitopes
5.	Antibodies